Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5877161 | 0.96 | MAPT (0.40) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5875992 | 0.90 | ALDH1A1 (0.41) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5877093 | 0.89 | KMT2A (0.40) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5876744 | 0.89 | KMT2A (0.38) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5876548 | 0.89 | MAPT (0.50) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5876300 | 0.88 | KMT2A (0.43) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5877024 | 0.88 | KMT2A (0.37) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5876036 | 0.87 | KMT2A (0.42) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL5876798 | 0.86 | KMT2A (0.39) | KMT2AMEN1ALDH1A1LMNATP53 | |
| SCHEMBL5875943 | 0.86 | ALDH1A1 (0.38) | KMT2AMEN1MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | KMT2A 2326/4885MEN1 548/4885MAPT 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.